Frontier Ip Group — Portfolio: TVG & APHA awarded Innovate UK grant

(LSE:FIPP) Frontier IP Group announced that its portfolio company The Vaccine Group and APHA have been awarded a £500,000 Innovate UK/Defra grant to advance the development of a vaccine for bovine respiratory syncytial virus (BRSV). The grant will fund dose-finding studies, assessment of single-dose efficacy, and a Synergy Farm Health study focused on disease incidence and antibiotic use in English herds. The announcement builds on positive APHA calf trial results that were disclosed in November 2025. Frontier IP holds a 16.95% equity stake in The Vaccine Group. The Pirbright Institute estimates that BRSV costs the UK £54 million annually. Global costs of BRSV are estimated to be up to £5.6 billion. The grant is intended to support further development and validation of the BRSV vaccine candidate. The Synergy Farm Health study will specifically examine the impact of the vaccine on disease incidence and antibiotic usage. The positive results from the APHA calf trial are cited as a foundation for this next phase of research. The potential commercial upside for Frontier IP’s stake is highlighted if the vaccine development progresses successfully. The Vaccine Group and APHA are the main recipients of the Innovate UK/Defra grant. The announcement underscores the significance of BRSV as a disease with substantial economic impact in the UK and globally. The funding is expected to accelerate the pathway to commercialisation for the BRSV vaccine. The involvement of Synergy Farm Health and The Pirbright Institute is noted in the context of the study and cost estimates.